An Exploratory Clinical Study of Autologous Tumor Infiltrating Lymphocytes (TILs) in the Treatment of Recurrent and Refractory Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 17 Jun 2021
At a glance
- Drugs Autologous tumor infiltrating lymphocytes-OriginCell Therapeutics (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors OriginCell Therapeutics
Most Recent Events
- 17 Jun 2021 New trial record